Seizure and Migraine Treatments using Denosumab

Abstract

A novel pathogenesis underlying certain types of seizures and migraines is disclosed and the validated set of premises presented enable the deductive conclusion to be made that drugs that reduce the amount of calcium ions (Ca++) released from bone reduce seizure and migraine risk. The premises validated as true in the specifications include: 1) Known seizure and migraine triggers increase osteoclast mediated release of Ca++ from bone. 2) Increased Ca++ released from bone increases seizure and migraine risk by a) depolarization of nerve membranes, b) enhanced calcium channel mediated neurotransmitter release and increases muscle contractility by c) enhanced neurotransmitter release at the neuromuscular junction and d) enhanced removal of the tropomyosin block between actin and myosin. 3) Conversely, reducing Ca++ released from bone reduces seizure and migraine risk. 4) Denosumab reduces Ca++ released from bone. Therefore, denosumab reduces seizure and migraine risk.

1 . A method of treating seizures consisting of administering, to a patient in need thereof, a therapeutically effective amount of denosumab in a dosage form to inhibit release of calcium from bone. 
     
     
         2 . A method of treating migraines consisting of administering, to a patient in need thereof, a therapeutically effective amount of denosumab in a dosage form to inhibit release of calcium from bone.